XERS News and Press, Xeris Pharmaceuticals Inc. From 02/12/20

Zosano Pharma (NASDAQ: ZSAN )  -47%  after pricing stock offering. More news on: Zosano Pharma Corporation, PolarityTE, Inc., PDS Biotechnology Corporation, Stocks on the move, , Read more ...

Xeris Pharmaceuticals (NASDAQ: XERS ) has priced a 9M-share public offering at $4.15 each. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Gainers : Rexahn Pharmaceuticals (NASDAQ: REXN )  +85% . More news on: Rexahn Pharmaceuticals, Inc., Sprint Corporation, Genprex, Inc., Stocks on the move, , Read more ...

CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced an ...

Xeris Pharmaceuticals (NASDAQ: XERS) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are including IQVIA scripts for Gvoke and glucagon below for the week ended 1/31/2020. Please note that these numbers were affected by ...

Cellect Biotechnology (NASDAQ: APOP ) +141%  on new patents . More news on: Cellect Biotechnology Ltd., Apellis Pharmaceuticals, Inc., Advaxis, Inc., Stocks on the move, Read more ...

Gainers: XERS   +21.1% . OTCQB:KNWN   +11.6% . MCHP   +4.5% . CEI   +4.1% . ACOR   +3.7% . More news on: Xeris Pharmaceuticals, Inc., Know Labs, Inc., Microchip Technology Incorporated, Stocks on the move, , News on ETFs Read more ...

Thinly traded micro cap Xeris Pharmaceuticals (NASDAQ: XERS ) is up  19%  after hours in response to positive results from the in-clinic portion of a Phase 2 clinical trial evaluating ready-to-use (RTU) glucagon for the prevention of hypoglycemia (low blood sugar) in adults wit...

Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging it...

Of all the new science coming in through ASH 2019, one of the most important abstracts is this one from Roche (RHHBY). Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Recept...